Prompted by an April 2010 article written by expert Renee Popovits, JD, (www.behavioral.net/popovits1004) we asked readers how they felt about the current confidentiality law for substance use treatment information (42 CFR, Part 2). The results are in:
Do you think that the current confidentiality law for substance use treatment information (42 CFR, Part 2) ought to be changed?
- Yes 61.9%
- No 38.1%
Noteworthy comments from those in favor of change included:
- “[It is a] barrier to integration strategies and HIT [and] EMR connectivity among direct providers.
- “There seem[s] to be more secrecy around this than there is around nuclear weapons [and] makes it incredibly challenging to adequately coordinate care.”
- “New technologies and the need to effectively communicate within a professional network should have been important ten years ago. There are many occasions when the release of information provided by a patient/client and permitted by signature causes excess delay in communications that at times become critical to treatment and patient/client retention and/or redirection in the treatment process.”
Our latest poll, found on the left-hand side of our Web site, is:
What has been your organization’s greatest challenge in implementing an e-prescribing system?
- Choosing the software
- Training the physicians to use the system
- We don’t use e-prescribing
Share your experiences with e-prescribing in our comments box. For more information about implementing an e-prescribing system, read E-prescribing: Coming your way soon by Dennis Grantham, Senior Editor at www.behavioral.net/viewsontech1007.